Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
fulc · stock forecast · 17 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 17 Wall Street analysts in the past 3 months
Buy
17 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$4.00
Consensus
$3.60
+3.3% upside
Low
$3.00
Median: $4 · Last Close: $3.48
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$3.60
3.3% upside
High Target
$4
14.8%
Low Target
$3
-13.9%
Current Price
$3.48
as of today
Based on analyst price targets, the FULC stock price prediction for the next 12 months ranges from $3 to $4. The consensus FULC price forecast of $3.60 implies 3.3% upside from the current price of $3.48.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.49 | ↑ 0.00% |
1-day model range: $3.45–$3.52. Peak: $3.52 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · FULC · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-03 | JP Morgan | Downgrade ↓ | Overweight→Underweight |
| 2026-06-02 | Piper Sandler | Downgrade ↓ | Overweight→Underweight |
| 2026-06-02 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2026-06-02 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2026-06-02 | Stifel | Downgrade ↓ | Buy→Hold |
| 2026-06-02 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-12-11 | Truist Securities | Maintains | Buy→Buy |
| 2025-12-09 | B of A Securities | Maintains | Underperform→Underperform |
| 2025-12-08 | RBC Capital | Maintains | Sector Perform→Sector Perform |
| 2025-12-08 | Piper Sandler | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Fulcrum Therapeutics, Inc. (FULC) stock. Of the recent 86 rating actions, 9 were upgrades and 19 were downgrades. 17 analysts currently cover FULC.
Analyst Recommendation Trends
FULC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.4% YoY
Revenue Next Year
$361M
↑ 115722.9% YoY
EPS This Year
$-0.81
EPS Next Year
$-0.65
↓ 19.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast FULC EPS of $-0.81 for the current fiscal year, based on estimates from 9 analysts. The FULC revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FULC stock forecast is supported by two independent data sources: analyst consensus ratings from 17 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FULC price target is $3.60 (+3.3% upside), with an analyst consensus of Buy.
The FULC short-term stock prediction for tomorrow is $3.49 (+0.00%).
Fulcrum Therapeutics, Inc. trades on NASDAQ under the ticker FULC. The FULC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 41% of covering analysts.
Frequently asked questions
FULC forecast · 8 questionsAccording to 17 Wall Street analysts, the average 12-month FULC price target is $3.60, with a high forecast of $4.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +3.3% potential upside from the current price of $3.48.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.